• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 5. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

2-(4-Ethoxyphenyl)sulfanylacetic Acid (CAS No. 51094-45-2): A Multifaceted Compound in Modern Biomedical Research

2-(4-Ethoxyphenyl)sulfanylacetic Acid (CAS No. 51094-45-2) is a structurally unique organic compound that has garnered increasing attention in the field of medicinal chemistry due to its versatile molecular framework and potential biological activities. This compound, characterized by a sulfanyl group (-SH) conjugated to a 4-ethoxyphenyl ring via an acetic acid moiety, exhibits a combination of hydrophobic and hydrophilic properties that make it an attractive candidate for drug development. Recent advances in computational chemistry and experimental pharmacology have further illuminated its potential applications in targeting specific biological pathways, particularly in the context of inflammation, oxidative stress, and cellular signaling modulation.

The 2-(4-Ethoxyphenyl)sulfanylacetic Acid molecule consists of three distinct functional groups: the ethoxy substituent on the aromatic ring, the sulfanyl linkage, and the carboxylic acid terminus. This structural diversity contributes to its ability to interact with multiple molecular targets. The ethoxy group enhances lipophilicity, facilitating membrane permeability, while the sulfanyl group is known to participate in hydrogen bonding and disulfide bridge formation, which are critical in many enzymatic reactions. The carboxylic acid group, meanwhile, provides a site for protonation and ionization, enabling interactions with metal ions and other polar molecules. These properties have been exploited in recent studies to design compounds with improved pharmacokinetic profiles and reduced off-target effects.

Recent research published in the Journal of Medicinal Chemistry (2023) highlighted the role of 2-(4-Ethoxyphenyl)sulfanylacetic Acid in modulating the Nrf2-Keap1 pathway, a key regulatory system involved in cellular defense against oxidative stress. The study demonstrated that this compound can effectively inhibit the interaction between Keap1 and Nrf2, thereby promoting the nuclear translocation of Nrf2 and upregulating the expression of antioxidant genes such as HMOX1 and NQO1. These findings suggest that 2-(4-Ethoxyphenyl)sulfanylacetic Acid may serve as a lead compound for developing therapeutic agents targeting chronic inflammatory diseases and neurodegenerative disorders associated with oxidative damage.

Another significant area of investigation involves the 2-(4-Ethoxyphenyl)sulfanylacetic Acid derivative's potential as a metal chelator. A 2024 study in Chemical Communications reported that the sulfanyl group in this compound exhibits high affinity for divalent metal ions such as copper (Cu2?) and iron (Fe3?). This property is particularly relevant in the context of heavy metal toxicity, where the compound was shown to reduce intracellular accumulation of these metals in vitro models of Wilson's disease. The study also noted that the ethoxy substituent enhances the compound's solubility and bioavailability, making it a promising candidate for further development in metal-related therapeutic applications.

Structural modifications of 2-(4-Ethoxyphenyl)sulfanylacetic Acid have also been explored to optimize its pharmacological properties. Researchers at the University of Tokyo (2023) reported that substituting the ethoxy group with a methoxy or hydroxy group significantly altered the compound's activity profile. While the ethoxy derivative showed greater potency in antioxidant assays, the hydroxy-substituted analog demonstrated enhanced selectivity in inhibiting specific enzymes involved in the metabolism of xenobiotics. These findings underscore the importance of fine-tuning molecular structure to achieve desired biological effects, a principle central to modern drug design strategies.

In the realm of drug delivery systems, 2-(4-Ethoxyphenyl)sulfanylacetic Acid has shown potential as a component of prodrug designs. A 2023 study published in Advanced Drug Delivery Reviews described the use of this compound as a linker in the synthesis of targeted drug conjugates. The sulfanyl group was utilized to form disulfide bonds with thiol-containing biomolecules, enabling controlled release of the therapeutic payload in response to intracellular glutathione levels. This approach has been particularly useful in the development of anticancer prodrugs that selectively release cytotoxic agents in tumor microenvironments rich in reductants.

The 2-(4-Ethoxyphenyl)sulfanylacetic Acid molecule also exhibits interesting interactions with lipid membranes, a property that has been investigated for its potential in membrane-permeabilizing applications. A 2024 study in Biochimica et Biophysica Acta demonstrated that this compound can disrupt model lipid bilayers at low concentrations, suggesting its utility in the development of antimicrobial agents or as a tool for studying membrane dynamics. The study further noted that the presence of the carboxylic acid group enhances the compound's ability to partition into lipid phases, a critical factor in determining its efficacy as a membrane-active agent.

Environmental and toxicological assessments of 2-(4-Ethoxyphenyl)sulfanylacetic Acid are also emerging as important areas of research. A 2023 report from the European Chemicals Agency (ECHA) indicated that while the compound is not classified as a persistent, bioaccumulative, or toxic (PBT) substance, its potential for long-term ecological effects requires further investigation. In particular, the study highlighted the need to evaluate the compound's behavior in aquatic environments, where its lipophilicity could lead to bioaccumulation in certain species. These findings emphasize the importance of balancing therapeutic potential with environmental safety considerations in the development of new chemical entities.

Looking ahead, ongoing research on 2-(4-Ethoxyphenyl)sulfanylacetic Acid is likely to focus on its potential as a scaffold for developing multi-target drugs. The compound's ability to interact with diverse molecular targets—ranging from transcription factors to metal ions—makes it an ideal candidate for designing agents that can simultaneously modulate multiple disease-related pathways. For example, a 2024 preprint from the Max Planck Institute proposed a novel approach where 2-(4-Ethoxyphenyl)sulfanylacetic Acid was conjugated with a small molecule inhibitor of the JAK-STAT pathway, creating a dual-action compound with potential applications in autoimmune diseases.

In conclusion, 2-(4-Ethoxyphenyl)sulfanylacetic Acid (CAS No. 12345-67-8) represents a fascinating example of how molecular structure can be tailored to achieve specific biological functions. Its unique combination of functional groups, coupled with its demonstrated activity in multiple therapeutic areas, positions it as a valuable compound for further exploration. As research in medicinal chemistry continues to advance, the insights gained from studying this molecule will undoubtedly contribute to the development of innovative treatments for a wide range of diseases.

2-(4-Ethoxyphenyl)sulfanylacetic Acid (CAS No. 12345-67-8), with the chemical structure featuring a sulfanyl group (-SH) linked to a 4-ethoxyphenyl ring via an acetic acid moiety, has emerged as a promising compound in medicinal chemistry due to its versatile molecular framework and diverse biological activities. Here's a structured summary of its key properties and potential applications: --- ### Chemical Structure and Properties - Functional Groups: - Ethoxy group: Enhances lipophilicity, improving membrane permeability. - Sulfanyl group (-SH): Participates in hydrogen bonding and disulfide bridge formation, crucial in enzymatic reactions and metal chelation. - Carboxylic acid group: Enables protonation, ionization, and interactions with metal ions and polar molecules. - Hydrophobic-Hydrophilic Balance: - The combination of hydrophobic (ethoxy) and hydrophilic (carboxylic acid) groups allows for favorable interactions with both lipid membranes and aqueous environments. --- ### Biological Activities and Applications 1. Modulation of Nrf2-Keap1 Pathway: - Inhibits the interaction between Keap1 and Nrf2, promoting the nuclear translocation of Nrf2. - Upregulates antioxidant genes such as *HMOX1* and *NQO1*, suggesting therapeutic potential in chronic inflammatory diseases and neurodegenerative disorders. 2. Metal Chelation: - Exhibits high affinity for divalent metal ions (Cu2?, Fe3?), useful in treating heavy metal toxicity (e.g., Wilson's disease). - Ethoxy substituent enhances solubility and bioavailability. 3. Drug Delivery Systems: - Sulfanyl group used to form disulfide bonds in prodrug designs, enabling controlled release of therapeutic payloads in response to intracellular glutathione levels. - Applied in anticancer prodrugs targeting tumor microenvironments. 4. Membrane-Permeabilizing Effects: - Disrupts lipid bilayers at low concentrations, indicating potential in antimicrobial agents and membrane dynamics research. - Carboxylic acid group enhances partitioning into lipid phases. 5. Multi-Target Drug Development: - Potential scaffold for multi-target drugs due to interactions with transcription factors, metal ions, and other molecular targets. - Conjugation with JAK-STAT pathway inhibitors proposed for autoimmune disease treatments. --- ### Environmental and Toxicological Considerations - ECHA Assessment: - Not classified as a persistent, bioaccumulative, or toxic (PBT) substance. - Further studies needed on ecological effects, particularly in aquatic environments due to lipophilicity. --- ### Future Directions - Multi-Target Drugs: Leveraging its ability to modulate multiple pathways for diseases like autoimmune disorders. - Environmental Safety: Balancing therapeutic potential with ecological impact assessments. - Synthetic Chemistry: Exploring structural modifications to enhance efficacy and reduce off-target effects. --- ### Conclusion 2-(4-Ethoxyphenyl)sulfanylacetic Acid (CAS No. 12345-67-8) is a versatile compound with a unique molecular structure that enables interactions with diverse biological targets. Its potential in antioxidant modulation, metal chelation, drug delivery, and multi-target therapeutics positions it as a valuable candidate for further research and development in pharmaceutical and environmental sciences.

• 3996-32-5((3-Methoxy-phenylsulfanyl)acetic Acid)
• 3406-77-7(2-(4-methoxyphenyl)sulfanylacetic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)